Palliative and Supportive Care

cambridge.org/pax

Original Article

Cite this article: Shen MJ, Prigerson HG, Maciejewski PK, Daly B, Adelman R, McConnell Trevino KM (2024). A communication intervention to improve prognostic understanding and engagement in advance care planning among diverse advanced cancer patient–caregiver dyads: A pilot study. *Palliative and Supportive Care* 22, 10–18. https://doi.org/10.1017/S1478951523000901

Received: 19 January 2023 Revised: 01 May 2023 Accepted: 15 June 2023

Kevwords:

Cancer; Advance care planning; Communication; Caregiver

Corresponding author: Megan J. Shen; Email: mshen2@fredhutch.org

A communication intervention to improve prognostic understanding and engagement in advance care planning among diverse advanced cancer patient-caregiver dyads: A pilot study

Megan J. Shen, PH.D. 1 , Holly G. Prigerson, PH.D. 2, Paul K. Maciejewski, PH.D. 3, Bobby Daly, M.D., M.B.A. 4, Ronald Adelman, M.D. 2 and Kelly M. McConnell Trevino, PH.D. 5

¹Division of Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA, USA; ²Department of Medicine, Weill Cornell Medical College, New York, NY, USA; ³Department of Radiology, Weill Cornell Medical College, New York, NY, USA; ⁴Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA and ⁵Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Abstract

Objectives. Accurate prognostic understanding among patients with advanced cancer and their caregivers is associated with greater engagement in advance care planning (ACP) and receipt of goal-concordant care. Poor prognostic understanding is more prevalent among racial and ethnic minority patients. The purpose of this study was to examine the feasibility, acceptability, and impact of a patient–caregiver communication-based intervention to improve prognostic understanding, engagement in ACP, and completion of advance directives among a racially and ethnically diverse, urban sample of patients and their caregivers.

Methods. Patients with advanced cancer and their caregivers (n = 22 dyads) completed assessments of prognostic understanding, engagement in ACP, and completion of advance directives at baseline and post-intervention, Talking About Cancer (TAC). TAC is a 7-session intervention delivered remotely by licensed social workers that includes distress management and communication skills, review of prognosis, and information on ACP.

Results. TAC met a priori benchmarks for feasibility, acceptability, and fidelity. Prognostic understanding and engagement in ACP did not change over time. However, patients showed increases in completion of advance directives.

Significance of results. TAC was feasible, acceptable, and delivered with high fidelity. Involvement of caregivers in TAC may provide added layers of support to patients facing advanced cancer diagnoses, especially among racial and ethnic minorities. Trends indicated greater completion of advance directives but not in prognostic understanding or engagement in ACP. Future research is needed to optimize the intervention to improve acceptability, tailor to diverse patient populations, and examine the efficacy of TAC in a randomized controlled trial.

Introduction

Engagement in advance care planning (ACP) – which includes completion of do-not-resuscitate (DNR) orders, living wills, and health-care proxy forms as well as having end-of-life (EOL) care conversations with family and providers – is associated with better quality of life at the EOL (Garrido et al. 2015) and receipt of care consistent with patients' values (Detering et al. 2010). Patients with advanced cancer who have an accurate understanding of their prognosis are more likely to engage in ACP (Waite et al. 2013), prefer comfort care over aggressive care (Weeks et al. 1998), and receive goal-concordant care (Detering et al. 2010; Mack et al. 2010; Seale et al. 1997). These patients are also less likely to receive futile aggressive EOL care (Prigerson et al. 2023; Seale et al. 1997; Trice et al. 2009; Weissman et al. 2021), a notable relationship given robust evidence that aggressive EOL care does not increase survival (Prigerson et al. 2015) but is associated with poor patient quality of life (Mack et al. 2010; Prigerson et al. 2015) and caregiver bereavement adjustment (Garrido and Prigerson 2014; Wright et al. 2008). Despite the importance of prognostic understanding and engagement in ACP, less than half of patients with advanced cancer recognize they are terminally ill (Trevino et al. 2016; Yun et al. 2010), have EOL care

© The Author(s), 2023. Published by Cambridge University Press.





conversations (Garrido et al. 2014; Wright et al. 2008), or complete advance directives (Dow et al. 2010) (i.e., engage in ACP).

The problem of poor prognostic understanding and low engagement in ACP is common among underserved racial and ethnic groups. Only 11% of Latino patients with a prognosis of 6 months or less described themselves as terminally ill, compared to 39% of White patients (Smith et al. 2008). Similarly, only 12.9% of Black patients with a life expectancy of 6 months or less estimated their life expectancy within 12 months of their actual survival compared to 43.43% of White patients (Trevino et al. 2016). Compared to White patients, Black and Latino patients are also more likely to have misconceptions about ACP (Jonnalagadda et al. 2012), less likely to complete advance directives (Carr 2011; Kelly et al. 2021; LoPresti et al. 2016), and more likely to receive aggressive care at the EOL (LoPresti et al. 2016; Perry et al. 2021; Taylor et al. 2017). Despite these disparities, few interventions to improve prognostic understanding and engagement in ACP among racial and ethnic minority populations have been developed and tested (Teal and Street 2009).

Caregivers are a potentially strong yet overlooked target for intervention to improve ACP among racial and ethnic minority patients. Caregivers play an integral role in patients' care and decision-making (Sudore and Fried 2010; Winzelberg et al. 2005), especially among racial and ethnic minority patients for whom family and community members often actively participate in medical decision-making (Mead et al. 2013). When patients with advanced cancer and their caregivers have an accurate understanding of the patient's prognosis, patients are more likely to complete advance directives (e.g., health-care proxy, living will, DNR order) and prefer comfort care over aggressive care than when 1 or both dyad members have an inaccurate prognostic understanding (Shen et al. 2018; Trevino et al. 2019). Further, dyadic prognostic understanding predicts advance directive completion beyond individual patient and caregiver prognostic understanding (Shen et al. 2018). These findings highlight the importance of ensuring both patients and their caregivers understand the patient's prognosis accurately. Yet, in less than one-third of dyads, both the patient and caregiver accurately understand the patient's prognosis (Shen et al. 2018; Trevino et al. 2019).

Barriers to having a shared prognostic understanding between patients and caregivers include inadequate communication skills within the dyad and the influence of distress associated with discussing prognosis (Chekryn 1984; Kirchhoff et al. 2010). Nearly two-thirds (65%) of caregivers of patients with advanced cancer report experiencing challenges communicating with the patient, particularly about emotionally distressing topics such as fears of treatment futility (Zhang and Siminoff 2003). These communication problems are associated with higher caregiver burden (Fried et al. 2005). Patients also endorse communication concerns, specifically that discussing ACP will damage their relationship with their caregiver (Schickedanz et al. 2009). Further, the emotional distress associated with these topics exacerbates avoidance of conversations about prognosis (Baik and Adams 2011; Manne et al. 1999; Zhang and Siminoff 2003) and likely contributes to patientcaregiver disagreement about the patient's prognosis (Zhang and Siminoff 2003). Despite these factors and a clear need to help patients and caregivers discuss prognosis and ACP, few interventions around ACP and prognostic understanding exist that target the poor communication and distress dyads face.

The purpose of this pilot study is to evaluate the feasibility, acceptability, and pre-post impact of a communication intervention (Talking About Cancer [TAC]) on prognostic understanding,

engagement in ACP, and completion of advance directives among a diverse, urban sample of patients with advanced cancer and their caregivers. We hypothesized that the intervention would be feasible and acceptable to patients and caregivers. In addition, we hypothesized that the intervention would be associated with an improvement in prognostic understanding, engagement in ACP, and completion of advance directives.

Methods

Participants and procedures

All study procedures were approved by the Institutional Review Boards of all participating sites. All participants provided informed consent. Patient-caregiver dyads were recruited from June 2020 to March 2022 (*Note*: All dyads except for n = 1 were recruited by June 2021. The final dyad was recruited in March 2022 due to unexpected internal delays at 1 of the sites due to staffing shortages and planned reductions in recruitment efforts as the conclusion of funding approached.) from 2 Northeast academic medical centers in an urban setting. Participants were identified through referrals from oncology providers and medical chart reviews by study staff. Eligible participants had a diagnosis of advanced cancer defined as follows: (1) locally advanced or metastatic cancer and/or (2) disease progression following at least first-line treatment. Additionally, eligible participants were aged 18 years or older, able to provide informed consent, able to identify a caregiver willing and able to participate in the study, fluent in English or Spanish, scored < 10 on the Blessed Orientation-Memory-Concentration Test or scored < 6 on the Short Portable Mental Status Questionnaire (Pfeiffer 1975), and able to communicate over the telephone. Caregivers were identified by the patient and defined as an unpaid individual who provides the patient with emotional, physical, and/or practical support. Eligible patients were also required to have had a discussion of prognosis with their oncologist to ensure they had the opportunity to understand their prognosis. Before patient enrollment, oncologists were asked whether they discussed any of the following with the patient: whether the cancer is curable, whether the cancer is terminal, or the patient's life expectancy. Patients whose oncologist reported discussing at least 1 of these topics with the patient were eligible to participate. Patients were excluded if they were too weak to complete study procedures, receiving hospice care at the time of study enrollment, currently being treated for schizophrenia, substance use or dependence, and/or bipolar disorder, or deemed inappropriate for the study by their treating oncologist.

Eligible caregivers were aged 18 years or older, fluent in English or Spanish, deemed to be cognitively capable of engaging in study procedures by study staff, and able to communicate over the telephone. Caregivers were excluded if they were too weak to complete study procedures or currently being treated for schizophrenia, substance use or dependence, and/or bipolar disorder.

Finally, dyads were excluded if both members endorsed an accurate understanding of the patient's illness as terminal with a prognosis of less than a year as prognostic understanding was the primary target of the intervention. We did this because the core content of TAC was focused on improving the accuracy of prognostic understanding. Patients and caregivers completed study measures administered by study staff over the telephone before starting the intervention and within approximately a week of completing the intervention. Patients and caregivers completed all measures separately and were compensated \$25 for completing baseline assessments and \$35 for completing follow-up assessments.

Intervention: Talking about Cancer (TAC)

The TAC intervention was informed by inhibitory learning theory (Blakev and Abramowitz 2016; Craske et al. 2008) and the cognitive-social processing theory of communication (Baik and Adams 2011; Cordova et al. 2001). These theories state that the anticipation of a negative outcome (e.g., partner distress), desire to protect others, and negative responses from others (e.g., criticism, invalidation) lead to avoidance of stressful events such as conversations about prognosis and poor processing of distressing cancer-related information. TAC reduces this avoidance by teaching patients and caregivers to express and manage their emotions while engaging in stressful conversations, thus promoting their ability to support each other during these conversations' (Baik and Adams 2011; Blakey and Abramowitz 2016; Bouton 2004; Manne et al. 2005; Scott et al. 2004; Shields and Rousseau 2004). The final version of TAC was informed by stakeholder feedback from patients, caregivers, and providers.

TAC is a 7-session weekly psychotherapy intervention delivered over the telephone by licensed social workers (see Table 1 for list of session topics) (In the current study, a total of n = 2 social workers delivered the intervention. All interventionists were informed patients had advanced cancer and poor prognosis.). Each session is 45–60 minutes in length. Session topics include the following: (a) Distress management strategies (Sessions 1 and 2) were informed by cognitive-behavioral therapy (Greer et al. 2012) and coping interventions (Manne et al. 2007, 2017) effective in patients with cancer and include deep breathing and relaxation strategies and cognitive restructuring techniques (Freeman 2004). (b) Communication skills (Sessions 3 and 4) were informed by Gottman's recommendations for couple communication (Gottman et al. 1976) and best practices for communicating in medical contexts (Brown and Bylund 2008) which highlight the skills of acknowledgment, validation, expressing empathy, asking open-ended questions, and verbalizing one's feelings with "I" statements (e.g., "When we talk about your treatment not working, I feel worried."). (c) Guided review of prognostic information (Sessions 5 and 6) was conducted using the distress management and communication skills reviewed in prior sessions to facilitate discussion of patients' and caregivers' interpretation of prognostic information previously provided by the patients' oncologist. (d) Advance care planning (Session 6) information is provided and previously learned communication skills are used to help patients identify their treatment preferences and communicate those preferences to loved ones and the medical team. (e) Intervention review and future planning (Session 7). The final session consists of a review of topics covered in the intervention and development of a plan for managing future difficult conversations.

Sessions 1 and 3 are conducted individually to provide the patient and caregiver with the opportunity to discuss their distress and communication strategies privately. All other sessions are conducted with the dyad to promote communication, coping, and engagement in ACP. The interventionist does not share information discussed in individual sessions with the dyad without permission from the patient or caregiver.

Measures

Demographic and disease characteristics

Patients reported their age, gender (male/female), race (White, Black, Asian, other), ethnicity (Latino vs non-Latino), education (college degree or less/post-graduate), income

Table 1. Talking about Cancer (TAC) session content

Session	Content
Session 1: Managing distress (Individual session)	Intervention overview and introduction to distress management
Session 2: Managing distress together (Dyadic session)	Distress management techniques to use together
Session 3: How to communicate (Individual session)	Basic communication strategies
Session 4: Communicating with your loved one (Dyadic session)	Communication about cancer
Session 5: Communicating about cancer (Dyadic session)	Discussion of prognostic information and distress management
Session 6: Advance care planning (Dyadic session)	How to discuss prognostic information and advance care planning
Session 7: Planning for the future (Dyadic session)	Wrap up and anticipation/plan- ning for future difficult conversations

(<\$21,000/≥\$21,000), employment (yes/no), insurance coverage (yes/no), parental status (children/no children), partner status (partnered/other), and patient–caregiver relationship type (e.g., spouse, parent/child). Disease characteristics were extracted from the medical record and included cancer type, stage, presence of metastasis, and treatments. Performance status was also extracted from the medical record and assessed with the Eastern Cooperative Oncology Group (ECOG) (Conill et al. 1990; Ma et al. 2010) and/or Karnofsky performance status (Karnofsky 1968).

Feasibility, acceptability, and treatment fidelity

Intervention *feasibility* was assessed with accrual and attrition rates as well as intervention session completion rates. Feasibility was defined as \geq 70% of eligible dyads enrolling in the study (Badr et al. 2015) and \geq 70% of dyads who enrolled in the study completing a majority of the sessions (i.e., 60%, which is 4 of the 7 intervention sessions).

Acceptability was assessed post-intervention. Patients and caregivers rated the overall perceived helpfulness of the intervention. This item was rated on a 5-point scale from "not at all helpful" (1) to "very helpful" (5). Patients and caregivers also completed multiple-choice questions assessing the acceptability of the number of TAC sessions, session frequency, and the amount of information in the intervention. Acceptability was defined as \geq 70% of patients and caregivers scoring \geq 4 on the 5-point Likert scale items. Finally, patients and caregivers rated intervention difficulty ("How difficult was it for you to understand the content of the intervention?"; 1 = not at all, 5 = very much) and overall satisfaction with the intervention delivery ("Did you like participating in the intervention over the telephone?": yes/no).

Treatment fidelity was assessed with a checklist that captured whether (1) core session content was delivered by study interventionists and (2) appropriate therapeutic techniques (e.g., shows positive regard, uses active listening skills) were used. These checklists were completed for a randomly selected 15% of intervention sessions by trained fidelity raters who listened to audio recordings intervention sessions. Fidelity was defined as delivering \geq 70%

of intervention components and using \geq 70% of the therapeutic techniques.

Prognostic understanding was assessed at baseline and 1 week post-intervention with items used previously in studies of patients with advanced cancer and their caregivers (Epstein et al. 2016; Mack et al. 2010). Patients' and caregivers' understanding of the terminal nature of the illness was assessed with the item: "How would you describe your/the patient's health status: (a) Relatively healthy, (b) Relatively healthy and terminally ill, (c) Seriously ill but not terminally ill, or (d) Seriously and terminally ill." Responses (a) and (c) were coded as "inaccurate" (not terminally ill) and responses (b) and (d) were coded as "accurate" (terminally ill) terminal illness understanding. Patients' and caregivers' understanding of the patient's life expectancy was assessed by asking: "When you think about your/the patient's life expectancy, do you think in terms of months or years?" A response of "months" was coded as accurate and "years" as inaccurate life expectancy understanding.

Engagement in ACP was assessed in patients using the Decision Maker (4 items; e.g., "Have you already decided who you want your medical decision maker to be?") and Quality of Life (4 items; e.g., "Have you already decided whether or not certain health situations would make your life not worth living?") subscales of the Advance Care Planning Engagement Survey: Action Measures (Sudore et al. 2013). Patients indicate whether they completed each ACP action (yes/no). A total count of "yes" responses for a score range of 0 to 4 is calculated; higher scores indicate greater engagement in ACP (Sudore et al. 2013; Van Scoy et al. 2019). These subscales are reliable and valid measures of concrete ACP behaviors. Caregiver engagement in ACP was assessed with a companion measure of the ACP Decision Maker subscale for caregivers (Van Scoy et al. 2019).

Completion of advance directives was assessed by asking patients whether they completed a DNR order and living will and identified a health-care proxy and/or durable power of attorney. To examine changes in completion of advance directives, a total score was computed that ranged from 0 = no advance directives completed to 3 = all completed (living will, health -care proxy, and DNR.

Statistical analyses

Descriptive statistics were used to examine feasibility, acceptability, fidelity, and pre- and post-intervention levels of prognostic understanding, engagement in ACP, and completion of advance directives.

Results

Patient demographic and disease characteristics

A total of n=22 dyads (n=22 patients and n=22 caregivers) were enrolled in the study. See Table 2 for patient and caregiver demographic characteristics. Patients had a mean age of 59.6 years (SD = 8.7) and 54.5% (n=12) identified as female. Patient reported race was the following: 18.2% (n=4) identified as White/Caucasian, 59.1% (n=13) identified as Black/African American, and 22.7% (n=5) identified as Other. For ethnicity, a total of 27.5% (n=6) patients identified as being Hispanic or Latino/Latina.

Caregivers had a mean age of 55.3 years (SD = 14.0) and 50.0% (n = 11) identified as female. Caregiver reported race was the following: 27.3% (n = 6) identified as White/Caucasian, 54.5% (n = 12) identified as Black/African American, 4.5% (n = 1) identified as Asian, and 9.1% (n = 2) identified as Other. For ethnicity,

Table 2. Patient and caregiver demographic characteristics

Characteristic	Patient, N (%)	Caregiver, N (%)
Age (continuous) [M(SD)]	59.6 (8.7)	55.3 (14.0)
Gender identity		
Gender		
Male	10 (45.5)	11 (50.0)
Female	12 (54.5)	11 (50.0)
Race		
White/Caucasian	4 (18.2)	6 (27.3)
Black/African American	13 (59.1)	12 (54.5)
Asian	-	1 (4.5)
Other (Hispanic or Latino/Latina)	5 (22.7)	2 (9.1)
Ethnicity		
Hispanic or Latino/Latina	6 (27.3)	4 (18.2)
Not Hispanic or Latino/Latina	16 (72.7)	18 (81.8)
Employed		
Yes	6 (27.3)	12 (54.5)
No	16 (72.7)	10 (45.5)
Married or partnered		
Yes	12 (54.6)	13 (59.1)
No	10 (45.4)	11 (40.9)
Have children		
Yes	17 (77.3)	14 (63.6)
No	5 (22.7)	8 (36.4)
College degree or higher		
Yes	12 (54.5)	11 (50.0)
No	10 (45.5)	11 (50.0)
Income (<\$21,000)		
Yes	5 (22.7)	4 (18.2)
No	14 (63.6)	11 (49.9)
Don't know	1 (4.5)	3 (13.6)
Refuse to answer	2 (9.1)	4 (18.2)
Health insurance coverage		
Yes	22 (100.0)	-
No	0 (0.0)	-
Informal caregiver type		
Spouse or partner	11 (50.0)	9 (40.9)
Sibling	3 (13.6)	2 (9.1)
Parent	3 (13.6)	0 (0.0)
Son or daughter	2 (9.1)	5 (22.7)
	2 (9.1)	3 (22.1)
Friend	3 (13.6)	4 (18.2)

a total of 18.2% (n = 4) caregivers identified as being Hispanic or Latino/Latina. The most common type of relationship with the patient reported was a spouse or partner (40.9%, n = 9), followed

Table 3. Patient clinical characteristics

Lung 5 (22.7%) Cervical 1 (4.5%) Ovarian 3 (13.6%) Uterine 2 (9.1%) Vulvar 1 (4.5%) Lymphoma 4 (18.2%) Other 2 (18.2%) Missing 2 (9.1%) Cancer stage (current) Stage II Stage III 1 (4.5%) Stage IV 16 (72.7%) Metastasis indicated Yes Yes 12 (54.5%) No 9 (40.9%) Missing 1 (4.5%) Chemotherapy Yes Yes 14 (63.6%) No 8 (36.4%) Radiation therapy Yes Yes 2 (9.1%) No 22 (100.0%) Immunotherapy Yes Yes 2 (9.1%) No 20 (90.9%) Targeted therapy Yes Yes 1 (4.5%) No 20 (90.9%) Karnofsky Performance Score 9.00 (1.58) ECOG Performance Score	Characteristic	Patient, M (SD)/N (%)		
Cervical 1 (4.5%) Ovarian 3 (13.6%) Uterine 2 (9.1%) Vulvar 1 (4.5%) Lymphoma 4 (18.2%) Other 2 (18.2%) Missing 2 (9.1%) Cancer stage (current) Total stage III Stage III 1 (4.5%) Stage IV 16 (72.7%) Metastasis indicated Total stage III Yes 12 (54.5%) No 9 (40.9%) Missing 1 (4.5%) Chemotherapy Yes Yes 14 (63.6%) No 8 (36.4%) Radiation therapy Yes Yes 0 (0.0%) No 22 (100.0%) Immunotherapy Yes Yes 2 (9.1%) No 20 (90.9%) Targeted therapy Yes 1 (4.5%) No 21 (95.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Cancer diagnoses			
Ovarian 3 (13.6%) Uterine 2 (9.1%) Vulvar 1 (4.5%) Lymphoma 4 (18.2%) Other 2 (18.2%) Missing 2 (9.1%) Cancer stage (current) Total (4.5%) Stage II 1 (4.5%) Stage IV 16 (72.7%) Metastasis indicated Total (54.5%) No 9 (40.9%) Missing 1 (4.5%) Chemotherapy Yes 14 (63.6%) No 8 (36.4%) Radiation therapy Yes 0 (0.0%) No 22 (100.0%) Immunotherapy Yes 2 (9.1%) No 20 (90.9%) Targeted therapy Yes 1 (4.5%) No 21 (95.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Lung	5 (22.7%)		
Uterine 2 (9.1%) Vulvar 1 (4.5%) Lymphoma 4 (18.2%) Other 2 (18.2%) Missing 2 (9.1%) Cancer stage (current) Tall (4.5%) Stage III 1 (4.5%) Stage IV 16 (72.7%) Metastasis indicated Tall (54.5%) No 9 (40.9%) Missing 1 (4.5%) Chemotherapy Tall (63.6%) No 8 (36.4%) Radiation therapy Tes Yes 0 (0.0%) No 22 (100.0%) Immunotherapy Tes Yes 2 (9.1%) No 20 (90.9%) Targeted therapy Tes Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Cervical	1 (4.5%)		
Vulvar 1 (4.5%) Lymphoma 4 (18.2%) Other 2 (18.2%) Missing 2 (9.1%) Cancer stage (current) Tall (4.5%) Stage III 1 (4.5%) Stage IV 16 (72.7%) Metastasis indicated Tall (54.5%) Yes 12 (54.5%) No 9 (40.9%) Missing 1 (4.5%) Chemotherapy Tall (63.6%) No 8 (36.4%) Radiation therapy Yes 0 (0.0%) No 22 (100.0%) Immunotherapy Yes 2 (9.1%) No 20 (90.9%) Targeted therapy Yes 1 (4.5%) No 21 (95.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Ovarian	3 (13.6%)		
Lymphoma 4 (18.2%) Other 2 (18.2%) Missing 2 (9.1%) Cancer stage (current) 1 (4.5%) Stage III 1 (4.5%) Stage IV 16 (72.7%) Metastasis indicated *** Yes 12 (54.5%) No 9 (40.9%) Missing 1 (4.5%) Chemotherapy *** Yes 14 (63.6%) No 8 (36.4%) Radiation therapy *** Yes 0 (0.0%) No 22 (100.0%) Immunotherapy *** Yes 2 (9.1%) No 20 (90.9%) Targeted therapy *** Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Uterine	2 (9.1%)		
Other 2 (18.2%) Missing 2 (9.1%) Cancer stage (current) 1 (4.5%) Stage III 1 (4.5%) Stage IV 16 (72.7%) Metastasis indicated 12 (54.5%) No 9 (40.9%) Missing 1 (4.5%) Chemotherapy Yes 14 (63.6%) No 8 (36.4%) Radiation therapy Yes 0 (0.0%) No 22 (100.0%) Immunotherapy Yes 2 (9.1%) No 20 (90.9%) Targeted therapy Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Vulvar	1 (4.5%)		
Missing 2 (9.1%) Cancer stage (current) 1 (4.5%) Stage III 1 (4.5%) Stage IV 16 (72.7%) Metastasis indicated 12 (54.5%) No 9 (40.9%) Missing 1 (4.5%) Chemotherapy Yes Yes 14 (63.6%) No 8 (36.4%) Radiation therapy Yes Yes 0 (0.0%) No 22 (100.0%) Immunotherapy Yes Yes 2 (9.1%) No 20 (90.9%) Targeted therapy Yes Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Lymphoma	4 (18.2%)		
Cancer stage (current) Stage II 1 (4.5%) Stage IV 16 (72.7%) Metastasis indicated Yes 12 (54.5%) No 9 (40.9%) Missing 1 (4.5%) Chemotherapy Yes 14 (63.6%) No 8 (36.4%) Radiation therapy Yes 0 (0.0%) No 22 (100.0%) Immunotherapy Yes 2 (9.1%) No 20 (90.9%) Targeted therapy Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Other	2 (18.2%)		
Stage II 1 (4.5%) Stage IV 16 (72.7%) Metastasis indicated	Missing	2 (9.1%)		
Stage III 1 (4.5%) Stage IV 16 (72.7%) Metastasis indicated 12 (54.5%) No 9 (40.9%) Missing 1 (4.5%) Chemotherapy Ves Yes 14 (63.6%) No 8 (36.4%) Radiation therapy Yes 0 (0.0%) No 22 (100.0%) Immunotherapy Yes 2 (9.1%) No 20 (90.9%) Targeted therapy Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Cancer stage (current)			
Stage IV 16 (72.7%) Metastasis indicated Yes 12 (54.5%) No 9 (40.9%) Missing 1 (4.5%) Chemotherapy Yes 14 (63.6%) No 8 (36.4%) Radiation therapy Yes 0 (0.0%) No 22 (100.0%) Immunotherapy Yes 2 (9.1%) No 20 (90.9%) Targeted therapy Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Stage II	1 (4.5%)		
Metastasis indicated Yes 12 (54.5%) No 9 (40.9%) Missing 1 (4.5%) Chemotherapy The second of the se	Stage III	1 (4.5%)		
Yes 12 (54.5%) No 9 (40.9%) Missing 1 (4.5%) Chemotherapy	Stage IV	16 (72.7%)		
No 9 (40.9%) Missing 1 (4.5%) Chemotherapy 14 (63.6%) No 8 (36.4%) Radiation therapy Ves 0 (0.0%) No 22 (100.0%) Immunotherapy Yes 2 (9.1%) No 20 (90.9%) Targeted therapy Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Metastasis indicated			
Missing 1 (4.5%) Chemotherapy 14 (63.6%) No 8 (36.4%) Radiation therapy Ves 0 (0.0%) No 22 (100.0%) Immunotherapy Yes 2 (9.1%) No 20 (90.9%) Targeted therapy Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Yes	12 (54.5%)		
Chemotherapy Yes 14 (63.6%) No 8 (36.4%) Radiation therapy Ves Yes 0 (0.0%) No 22 (100.0%) Immunotherapy Yes 2 (9.1%) No 20 (90.9%) Targeted therapy Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	No	9 (40.9%)		
Yes 14 (63.6%) No 8 (36.4%) Radiation therapy Ves 0 (0.0%) No 22 (100.0%) Immunotherapy Ves 2 (9.1%) No 20 (90.9%) Targeted therapy Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Missing	1 (4.5%)		
No 8 (36.4%) Radiation therapy 0 (0.0%) Yes 0 (0.0%) No 22 (100.0%) Immunotherapy 2 (9.1%) No 20 (90.9%) Targeted therapy Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Chemotherapy			
Radiation therapy Yes 0 (0.0%) No 22 (100.0%) Immunotherapy Yes 2 (9.1%) No 20 (90.9%) Targeted therapy Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Yes	14 (63.6%)		
Yes 0 (0.0%) No 22 (100.0%) Immunotherapy 2 (9.1%) Yes 2 (9.1%) No 20 (90.9%) Targeted therapy Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	No	8 (36.4%)		
No 22 (100.0%) Immunotherapy 2 (9.1%) Yes 2 (9.1%) No 20 (90.9%) Targeted therapy 4 (4.5%) Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Radiation therapy			
Immunotherapy Yes 2 (9.1%) No 20 (90.9%) Targeted therapy 1 (4.5%) Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Yes	0 (0.0%)		
Yes 2 (9.1%) No 20 (90.9%) Targeted therapy Targeted therapy Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	No	22 (100.0%)		
No 20 (90.9%) Targeted therapy 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Immunotherapy			
Targeted therapy Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Yes	2 (9.1%)		
Yes 1 (4.5%) No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	No	20 (90.9%)		
No 21 (95.5%) Karnofsky Performance Score 9.00 (1.58)	Targeted therapy			
Karnofsky Performance Score 9.00 (1.58)	Yes	1 (4.5%)		
·	No	21 (95.5%)		
ECOG Performance Score 1.41 (2.27)	Karnofsky Performance Score	9.00 (1.58)		
	ECOG Performance Score	1.41 (2.27)		

Note: All information taken from medical record.

M = mean, SD = standard deviation, ECOG = Eastern Cooperative Oncology Group.

by son or daughter (22.7%, n = 5) and friend (18.2%, n = 4). The majority caregivers reported living with the patient (54.5%, n = 12).

See Table 3 for patient clinical characteristics. The most common cancer diagnoses included lung (22.7%, n = 5), lymphoma (18.2%, n = 2), and ovarian (13.6%, n = 3). The majority (72.7%, n = 16) of patients had stage IV cancer and metastatic disease (54.5%, n = 12).

Intervention feasibility

Feasibility was defined in the present study as \geq 70% of eligible dyads enrolling in the study (Badr et al. 2015) and \geq 70% of dyads who enrolled in the study completing at least 4 of the intervention

sessions. A total of 165 patients were attempted to be reached for the study. Of these, n = 91 patients were deemed ineligible, leaving a total of n = 74 patients deemed eligible to approach. Of these n = 74 patients, n = 52 refused to participate before determining full eligibility and n = 22 patients consented to the study and were deemed eligible. Of these 22 patients, all 22 enrolled in the study and completed baseline assessments. Of the n = 22 dyads participating in the intervention (n = 44 participants), n = 15 dyads (68.2%) completed at least the first 4 sessions of the intervention and n = 12 (54.5%) completed all 7 intervention sessions. Session completion was as follows: 1 session (n = 18 dyads), 2 sessions (n = 17 dyads), 3 sessions (n = 16 dyads), 4 sessions (n = 15 dyads), 5 sessions (n = 14 dyads), and 6 and 7 sessions (n = 12 dyads). The most common reason for attrition among dyads included time constraint (n = 3), lost to follow-up/passive withdrawal (n = 3), and too weak to complete (n = 1).

Intervention acceptability

Among the 22 dyads who enrolled in the study and completed baseline measures, 13 patients and 12 caregivers provided post-intervention data. Of these, n=12 dyads were full completers (i.e., all 7 sessions), and 1 patient was a semi-completer (i.e., <7 sessions). All patients who had post-intervention data (n=13) rated the intervention as helpful (n=11 rated it as a "5" or very helpful; n=2 rated it as a "4"). Most patients (n=9, 69.2%) indicated the intervention had an acceptable number of sessions. Most patients (n=11, 84.6%) indicated that the session frequency of weekly was acceptable and that the intervention had the right amount of information. Most patients (n=12, 92.3%) rated it as "not at all difficult" and were satisfied (92.3%) with participating in the intervention over the telephone.

Similarly, all caregivers (n=12) rated the intervention as helpful (n=8) rated it as "5" or very helpful; n=3 rated it as "4" and n=1 rated it as "3" or moderately helpful"). Most caregivers (n=9,75.0%) indicated the intervention had an acceptable number of sessions. Most caregivers (n=10,83.3%) indicated that the session frequency of weekly was acceptable. All caregivers (n=12,100.0%) said the intervention had the right amount of information. Most caregivers (n=11,91.7%) rated it as "not at all difficult" and reported satisfaction (91.7%) with participating in the intervention over the telephone. Across all 3 measures, the a priori benchmark for intervention acceptability of $\geq 70\%$ of patients and caregivers scoring ≥ 4 on the Likert scale items was met.

Treatment fidelity

Fidelity was defined as delivering \geq 70% of core intervention components and using \geq 70% of the therapeutic techniques. For the core intervention components, interventionists delivered 162 of 208 possible components across all patients and caregivers for a 77.9% fidelity rate. For therapeutic techniques, interventionists used 281 of 288 possible techniques across the sample for a 97.6% fidelity rate, thereby meeting the a priori fidelity benchmark.

Outcomes

Prognostic understanding

At baseline, 3 of 13 (23.1%) patients had an accurate understanding of the terminal nature of their illness. Post-intervention, 2 of 13 (15.4%) had an accurate understanding. At baseline, 2 of 13

Table 4. Patient and caregiver prognostic understanding

Dyad	Patient Pre	Patient Post	CG Pre	CG Post
Termina	l illness understan	nding		
1	Accurate	Inaccurate	Inaccurate	Inaccurate
2	Inaccurate	Inaccurate	Inaccurate	Inaccurate
3	Inaccurate	Inaccurate	Inaccurate	Inaccurate
4	Accurate	Accurate	Inaccurate	Inaccurate
5	Inaccurate	Inaccurate	Inaccurate	-
6	Inaccurate	Inaccurate	Inaccurate	Inaccurate
7	Accurate	Inaccurate	Accurate	Accurate
8	Inaccurate	Inaccurate	Inaccurate	Inaccurate
9	Inaccurate	Inaccurate	Inaccurate	Inaccurate
10	Inaccurate	Inaccurate	Inaccurate	Inaccurate
11	Inaccurate	Inaccurate	Inaccurate	Inaccurate
12	Inaccurate	Inaccurate	Inaccurate	Inaccurate
13	Inaccurate	Accurate	Accurate	Inaccurate
Life expe	ectancy			
1	Inaccurate	Accurate	Inaccurate	Inaccurate
2	Inaccurate	Inaccurate	Inaccurate	Inaccurate
3	Inaccurate	Inaccurate	Inaccurate	Inaccurate
4	Inaccurate	Accurate	Inaccurate	Inaccurate
5	Inaccurate	Inaccurate	Inaccurate	-
6	Inaccurate	Inaccurate	Inaccurate	Inaccurate
7	Inaccurate	Inaccurate	Inaccurate	Accurate
8	Inaccurate	Inaccurate	Inaccurate	Inaccurate
9	Inaccurate	Inaccurate	Inaccurate	Inaccurate
10	Inaccurate	Inaccurate	Inaccurate	Inaccurate
11	Inaccurate	Inaccurate	Inaccurate	Inaccurate
12	Inaccurate	Inaccurate	Inaccurate	Inaccurate
13	Inaccurate	Inaccurate	Inaccurate	Inaccurate
13				

CG = caregiver.

caregivers (15.4%) had an accurate understanding of the terminal nature of the patient's illness. Post-intervention, 1 of 12 (8.3%) had an accurate understanding. At baseline, 0 of 13 patients had an accurate understanding of their life expectancy (as months, not years). Post-intervention, 2 of 13 (15.4%) patients had an accurate understanding. At baseline, 0 of 13 caregivers had an accurate understanding of the patient's life expectancy. Post-intervention, 1 of 12 (8.3%) had an accurate understanding. See Table 4 for a breakdown of shifts in prognostic understanding by dyad at the patient and caregiver level. There were no consistent patterns of change within dyads.

Engagement in ACP

Patients reported a mean sum of 2.77 (SD = 1.42) on the ACP Decision-Maker subscale at baseline and a mean of 3.00 (SD = 1.35) post-intervention. Patients reported a mean sum score of 0.69 (SD = 1.03) on the ACP Quality of Life subscale at baseline and a mean sum score of 1.15 (SD = 0.99) post-intervention.

Caregivers reported a mean sum of 1.69 (SD = 1.55) on the ACP Decision-Maker subscale at baseline and a mean sum of 1.50 (SD = 1.38) post-intervention.

Completion of advance directives

For DNR order, a total of 1 patient (7.7%) reported having a DNR order at baseline and 4 patients (30.8%) reported having completed 1 post-intervention. For living wills, a total of 2 patients (15.4%) reported completing 1 at baseline and 3 patients (23.1%) reported completing 1 post-intervention. For health-care proxy forms, a total of 6 patients (50.0%) reported completing 1 at baseline and 9 (69.2%) reported completing 1 post-intervention.

Discussion

This pilot single-arm trial examined the feasibility, acceptability, fidelity, and pre-post impact of a communication-based intervention, designed to improve prognostic understanding and engagement in ACP among patients with terminally ill cancer and their caregivers. Results indicate that the TAC intervention was feasible, acceptable, and that the social worker interventionists delivered it with high fidelity. Rates of enrollment exceeded the a priori benchmark while rates of completion fell slightly below the benchmark of feasibility. Still, over half of patients and caregivers completed all 7 sessions of the intervention. Nevertheless, because only about 60% of dyads fully completed the intervention, a reduction in number of sessions appears warranted and may enhance feasibility of the TAC intervention. Patients and caregivers also exceeded the a priori benchmarks for acceptability, with most patients and caregivers rating the intervention as very helpful, an acceptable length, and not at all difficult. Further, patients and caregivers were satisfied with telephone delivery of the intervention. Intervention fidelity was extremely high and greatly exceeded a priori benchmarks for fidelity.

Preliminary intervention testing was limited by the small sample size; however, results indicate a trend towards an increase in completion of advance directives but not in prognostic understanding or engagement in ACP. This finding may be because the TAC intervention had an entire session devoted to specifics around how to complete advance directives (session 6), whereas prognostic understanding was discussed more generally. TAC content around prognostic understanding focused on how to talk about prognosis with one's doctor and about poor prognosis in general. Information on an individual's prognosis was not provided during the intervention, as this is outside the scope of practice for mental health providers. Because there was a shift in some patients' and caregivers' prognostic understanding from accurate to inaccurate, there is a clear need for further refinement of TAC's discussion of prognostic understanding. Additionally, future iterations of delivering TAC may need more direct involvement or communication about prognostic understanding from the medical team.

In contrast to the findings around prognostic understanding, results from this study indicate the potential for TAC to improve advance directive completion is promising. Information in TAC on the nature and importance of advance directives and how to complete them is concrete and applicable to patients with varying levels of prognostic understanding, and preliminary results indicate trends in the direction of increases in engagement in advance directive completion. Given the limited efficacy of prior interventions targeting advance directive completion, this is an especially promising finding. A systematic review across 55 studies found that ACP interventions increase completion of advance directives

at very limited rates (e.g., a 5% increase in completion of health-care proxy forms (Rubin et al. 1994)). More recent interventions yield more promising results with advance completion rates as high as 35% (Sudore et al. 2017), yet there remains significant room for improvement.

A significant strength of this study is the racial and ethnic diversity of the study sample. Racial and ethnic minority patients, particularly patients identifying as black or Hispanic or Latino, suffer from significantly lower rates of advance directive completion than white patients (Carr 2011; Kelly et al. 2021; LoPresti et al. 2016). The inclusion of caregivers in TAC is particularly important for patients from racial and ethnic minority groups for whom caregivers play an especially prominent role in patient decisionmaking and care (Mead et al. 2013). Furthermore, integration of caregivers into the ACP process is an explicitly expressed preference of patients from racial and ethnic minority groups (Sanders et al. 2019; Shen et al. 2020). Despite this high need, few ACP interventions have taken a dyadic approach to the ACP process. As such, TAC holds promise as a potentially effective intervention to improve advance directive completion among Black and Hispanic or Latino patients and reduce racial disparities in ACP.

TAC was developed with feedback from a variety of patients, including Hispanic/Latino and Black patients. As a result, some cultural tailoring occurred during the intervention development process. However, cultural tailoring was not a primary focus in this preliminary process and the open trial described here revealed additional needed changes to improve cultural specificity. For instance, although attempts were made to make an intervention that could be administered to multiple racial and ethnic groups, variations in cultural norms around prognosis and prognostic discussions may necessitate more specific tailoring for each racial and ethnic groups and/or socioeconomic class. Such tailoring may result in more effective targeting of prognostic understanding. Additionally, highly under resourced dyads including those who were unhoused and living in shelters were eager to participate in the TAC intervention. Many dyads were unable to finish all 7 sessions due to obstacles such as time restraints and limited access to a phone. Future research that identifies unnecessary content to reduce the number of TAC sessions may improve feasibility, particularly for patients with resource limitations.

Combined, preliminary data indicate that future modifications need to be made to not only culturally tailor but overall improve TAC's feasibility and potential efficacy. First, future content should focus more explicitly on prognostic understanding. The current content is likely too vague and focuses on simply guiding dyads in how to have conversations with their providers. This may not have been a direct enough form of communication about prognosis. Future research should examine best ways to be more explicit about poor prognosis and potentially integrate the medical team more directly. Second, TAC should incorporate more material that focuses on guiding dyads in how to engage in ACP, including checklists for specific tasks to complete in the ACP process. Finally, TAC would benefit from shortening the number of sessions. For instance, the topic of ACP was a feature of the intervention dyads reported liking, while many noted that the distress management and communication techniques were too basic or did not need to be covered in such great detail. As such, Sessions 1 through 5 could be shortened to focus on core components of distress management and communication techniques. This would allow for a greater focus on prognostic understanding and ACP while shortening the intervention.

Limitations of the study must be acknowledged in interpreting results. First, the small sample size and pre-post design limits the ability to examine the efficacy of TAC, control for factors (e.g., demographic variables) that may impact treatment effects, and generalize study findings. As such, a larger randomized controlled trial is needed to examine the efficacy of this intervention on engagement in ACP and advance directive completion. In addition, future larger studies should examine the impact of TAC on care received at the EOL with a focus on provision of care that is consistent with patients' preferences. Second, this study was conducted at 2 major academic medical centers in an urban setting which limits the generalizability of study findings. However, 1 site provided care to a historically underserved patient population which is a notable study strength. Third, patients and caregivers were excluded from the study if both had an accurate prognostic understanding; however, it is possible these individuals may have needed assistance with advance directive completion and, therefore, could have benefitted from the intervention.

Conclusion

In summary, results from this study indicate that the TAC intervention is feasible and acceptable with the potential to improve advance directive completion among Black and Hispanic or Latino patients with advanced cancer. These findings point to a possible new intervention designed to target patients' engagement in ACP through integration of their caregivers in this process. Future research is needed to further refine and optimize TAC to diverse patient and caregiver populations and to examine the efficacy of TAC to improve engagement in ACP and advance directive completion and increase rates of preference-concordant end-of life care.

Acknowledgments. The authors would like to thank Madeline Rogers, Claudia De Los Santos, Robin Hershkowitz, Amy Stern, Jasmine Monterio, Chrystal Marte, and James Lassen for their work in delivering the intervention (MR, RH, AS, JM), providing feedback, (MR, CDLS, JM), and helping coordinate and oversee patient recruitment (CDLS, CM, JL).

Funding. This research was funded through NCI R21-CA224874 and in part through the following grants: K07CA207580 (MJS), the P30 CA008748 from the NIH/NCI Cancer Center Support Grant, and the UL1 TR002384 (WCM CTSC) from the National Center for Advancing Translational Sciences.

Competing interests. None.

References

Badr H, Smith CB, Goldstein NE, et al. (2015) Dyadic psychosocial intervention for advanced lung cancer patients and their family caregivers: Results of a randomized pilot trial. Cancer 121(1), 150–158. doi:10.1002/cncr.29009

Baik OM and Adams KB (2011) Improving the well-being of couples facing cancer: A review of couples-based psychosocial interventions. *Journal of Marital and Family Therapy* 37(2), 250–266. doi:10.1111/j.1752-0606.2010. 00217.x

Blakey SM and Abramowitz JS (2016) The effects of safety behaviors during exposure therapy for anxiety: Critical analysis from an inhibitory learning perspective. *Clinical Psychology Review* **49**, 1–15. doi:10.1016/j.cpr.2016.07.

Bouton ME (2004) Context and behavioral processes in extinction. Learning & Memory 11(5), 485–494. doi:10.1101/lm.78804

- **Brown RF and Bylund CL** (2008) Communication skills training: Describing a new conceptual model. *Academic Medicine* **83**(1), 37–44. doi:10.1097/ACM. 0b013e31815c631e
- Carr D (2011) Racial differences in end-of-life planning: Why don't Blacks and Latinos prepare for the inevitable? *OMEGA–Journal of Death and Dying* **63**(1), 1–20. doi:10.2190/OM.63.1.a
- Chekryn J (1984) Cancer recurrence: Personal meaning, communication, and marital adjustment. Cancer Nursing 7(6), 491–498. doi:10.1097/00002820-198412000-00005
- Conill C, Verger E and Salamero M (1990) Performance status assessment in cancer patients. *Cancer* **65**(8), 1864–1866. doi:10.1002/1097-0142(19900415)65:8<1864::AID-CNCR2820650832>3.0.CO;2-U
- Cordova MJ, Cunningham LL, Carlson CR, et al. (2001) Social constraints, cognitive processing, and adjustment to breast cancer. *Journal of Consulting and Clinical Psychology* **69**(4), 706–711. doi:10.1037/0022-006X.69.4.706
- Craske MG, Kircanski K, Zelikowsky M, et al. (2008) Optimizing inhibitory learning during exposure therapy. Behaviour Research and Therapy 46(1), 5–27. doi:10.1016/j.brat.2007.10.003
- **Detering KM, Hancock AD, Reade MC**, *et al.* (2010) The impact of advance care planning on end of life care in elderly patients: Randomised controlled trial. *BMJ* **340**, c1345. doi:10.1136/bmj.c1345
- Dow LA, Matsuyama RK, Ramakrishnan V, et al. (2010) Paradoxes in advance care planning: The complex relationship of oncology patients, their physicians, and advance medical directives. *Journal of Clinical Oncology* 28(2), 299–304. doi:10.1200/JCO.2009.24.6397
- Epstein AS, Prigerson HG, O'Reilly EM, et al. (2016) Discussions of life expectancy and changes in illness understanding in patients with advanced cancer. Journal of Clinical Oncology 34(20), 2398–2403. doi:10.1200/JCO. 2015.63.6696
- Freeman A (2004) Clinical Applications of Cognitive Therapy. Plenum, NY: Springer Science & Business Media.
- Fried TR, Bradley EH, O'Leary JR, et al. (2005) Unmet desire for caregiverpatient communication and increased caregiver burden. *Journal of the American Geriatrics Society* **53**(1), 59–65. doi:10.1111/j.1532-5415.2005. 53011.x
- Garrido MM, Balboni TA, Maciejewski PK, et al. (2015) Quality of life and cost of care at the end of life: The role of advance directives. *Journal of Pain and Symptom Management* 49(5), 828–835. doi:10.1016/j.jpainsymman. 2014.09.015
- Garrido MM, Harrington ST and Prigerson HG (2014) End-of-life treatment preferences: A key to reducing ethnic/racial disparities in advance care planning? *Cancer* **120**(24), 3981–3986. doi:10.1002/cncr.28970
- Garrido MM and Prigerson HG (2014) The end-of-life experience: Modifiable predictors of caregivers' bereavement adjustment. *Cancer* 120(6), 918–925. doi:10.1002/cncr.28495
- Gottman J, Notarius C, Gonso J, et al. (1976) A Couple's Guide to Communication. Research Pr Pub.
- Greer JA, Traeger L, Bemis H, et al. (2012) A pilot randomized controlled trial of brief cognitive-behavioral therapy for anxiety in patients with terminal cancer. *The Oncologist* 17(10), 1337–1345. doi:10.1634/theoncologist.2012-
- Jonnalagadda S, Lin JJ, Nelson JE, et al. (2012) Racial and ethnic differences in beliefs about lung cancer care. Chest 142(5), 1251–1258. doi:10.1378/chest. 12-0330
- **Karnofsky DA** (1968) Determining the extent of the cancer and clinical planning for cure. *Cancer* **22**(4), 730–734. doi:10.1002/1097-0142(196810)22:4<730::AID-CNCR2820220407>3.0.CO;2-H
- Kelly EP, Henderson B, Hyer M, et al. (2021) Intrapersonal factors impact advance care planning among cancer patients. American Journal of Hospice and Palliative Medicine* 38(8), 907–913. doi:10.1177/1049909120962457
- **Kirchhoff KT, Hammes BJ, Kehl KA**, *et al.* (2010) Effect of a disease-specific planning intervention on surrogate understanding of patient goals for future medical treatment. *Journal of the American Geriatrics Society* **58**(7), 1233–1240. doi:10.1111/j.1532-5415.2010.02760.x
- LoPresti MA, Dement F and Gold HT (2016) End-of-life care for people with cancer from ethnic minority groups: A systematic review. American Journal of Hospice and Palliative Medicine* 33(3), 291–305. doi:10.1177/1049909114565658

- Ma C, Bandukwala S, Burman D, et al. (2010) Interconversion of three measures of performance status: An empirical analysis. European Journal of Cancer 46(18), 3175–3183. doi:10.1016/j.ejca.2010.06.126
- Mack JW, Weeks JC, Wright AA, et al. (2010) End-of-life discussions, goal attainment, and distress at the end of life: Predictors and outcomes of receipt of care consistent with preferences. Journal of Clinical Oncology 28(7), 1203–1208. doi:10.1200/JCO.2009.25.4672
- Manne S, Dougherty J, Veach S, et al. (1999) Hiding worries from one's spouse: Protective buffering among cancer patients and their spouses. Cancer Research Therapy and Control 8, 175–188.
- Manne SL, Ostroff JS, Winkel G, et al. (2005) Couple-focused group intervention for women with early stage breast cancer. *Journal of Consulting and Clinical Psychology* **73**(4), 634. doi:10.1037/0022-006X.73.4.634
- Manne SL, Rubin S, Edelson M, et al. (2007) Coping and communicationenhancing intervention versus supportive counseling for women diagnosed with gynecological cancers. *Journal of Consulting and Clinical Psychology* 75(4), 615–628. doi:10.1037/0022-006X.75.4.615
- Manne SL, Virtue SM, Ozga M, et al. (2017) A comparison of two psychological interventions for newly-diagnosed gynecological cancer patients. *Gynecologic Oncology* **144**(2), 354–362. doi:10.1016/j.ygyno.2016. 11.025
- Mead EL, Doorenbos AZ, Javid SH, et al. (2013) Shared decision-making for cancer care among racial and ethnic minorities: A systematic review. American Journal of Public Health 103(12), e15–e29. doi:10.2105/AJPH. 2013.301631
- Perry LM, Walsh LE, Horswell R, et al. (2021) Racial disparities in end-of-life care between black and white adults with metastatic cancer. Journal of Pain and Symptom Management 61(2), 342–9.e1. doi:10.1016/j.jpainsymman. 2020.09.017
- **Pfeiffer E** (1975) A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. *Journal of the American Geriatrics Society* **23**(10), 433–441. doi:10.1111/j.1532-5415.1975.tb00927.x
- Prigerson HG, Bao Y, Shah MA, et al. (2015) Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncology 1(6), 778–784. doi:10.1001/jamaoncol.2015.2378
- Prigerson HG, Viola M, Maciejewski PK, et al. (2023) Advance care planning (ACP) to promote receipt of value-concordant care: Results vary according to patient priorities. PLoS One 18(1), e0280197. doi:10.1371/journal.pone. 0280197
- Rubin SM, Strull WM, Fialkow MF, et al. (1994) Increasing the completion of the durable power of attorney for health care: A randomized, controlled trial. JAMA 271(3), 209–212. doi:10.1001/jama.1994.03510270055039
- Sanders JJ, Johnson KS, Cannady K, et al. (2019) From barriers to assets: Rethinking factors impacting advance care planning for African Americans. Palliative & Supportive Care 17(3), 306–313. doi:10.1017/S147895151800038X
- Schickedanz AD, Schillinger D, Landefeld CS, et al. (2009) A clinical framework for improving the Advance Care Planning process: Start with patients' self-identified barriers. *Journal of the American Geriatrics Society* **57**(1), 31–39. doi:10.1111/j.1532-5415.2008.02093.x
- Scott JL, Halford WK and Ward BG (2004) United we stand? The effects of a couple-coping intervention on adjustment to early stage breast or gynecological cancer. *Journal of Consulting and Clinical Psychology* 72(6), 1122. doi:10.1037/0022-006X.72.6.1122
- Seale C, Addington-Hall J and McCarthy M (1997) Awareness of dying: Prevalence, causes and consequences. Social Science & Medicine 45(3), 477–484. doi:10.1016/S0277-9536(96)00379-6
- Shen MJ, Gonzalez C, Leach B, et al. (2020) An examination of Latino advanced cancer patients' and their informal caregivers' preferences for communication about advance care planning: A qualitative study. Palliative & Supportive Care 18(3), 277–284. doi:10.1017/S1478951519000890
- Shen MJ, Trevino KM and Prigerson HG (2018) The interactive effect of advanced cancer patient and caregiver prognostic understanding on patients' completion of Do Not Resuscitate orders. *Psycho-Oncology* 27(7), 1765–1771. doi:10.1002/pon.4723
- Shields CG and Rousseau SJ (2004) A pilot study of an intervention for breast cancer survivors and their spouses. *Family Process* **43**(1), 95–107. doi:10. 1111/j.1545-5300.2004.04301008.x

Smith AK, McCarthy EP, Paulk E, et al. (2008) Racial and ethnic differences in advance care planning among patients with cancer: Impact of terminal illness acknowledgment, religiousness, and treatment preferences. *Journal of Clinical Oncology* 26(25), 4131–4137. doi:10.1200/JCO.2007.14.8452

- Sudore RL, Boscardin J, Feuz MA, et al. (2017) Effect of the PREPARE website vs an easy-to-read advance directive on advance care planning documentation and engagement among Veterans: A randomized clinical trial. JAMA Internal Medicine 177(8), 1102–1109. doi:10.1001/jamainternmed. 2017.1607
- Sudore RL and Fried TR (2010) Redefining the "planning" in advance care planning: Preparing for end-of-life decision making. Annals of Internal Medicine 153(4), 256–261. doi:10.7326/0003-4819-153-4-201008170-00008
- Sudore RL, Stewart AL, Knight SJ, et al. (2013) Development and validation of a questionnaire to detect behavior change in multiple advance care planning behaviors. PLoS One 8(9), e72465. doi:10.1371/journal.pone. 0072465
- Taylor JS, Rajan SS, Zhang N, et al. (2017) End-of-life racial and ethnic disparities among patients with ovarian cancer. Journal of Clinical Oncology 35(16), 1829–1835. doi:10.1200/JCO.2016.70.2894
- **Teal CR and Street RL** (2009) Critical elements of culturally competent communication in the medical encounter: A review and model. *Social Science & Medicine* **68**(3), 533−543. doi:10.1016/j.socscimed.2008.10.015
- Trevino KM, Prigerson HG, Shen MJ, et al. (2019) Association between advanced cancer patient-caregiver agreement regarding prognosis and hospice enrollment. Cancer 125(18), 3259–3265. doi:10.1002/cncr.32188
- Trevino KM, Zhang B, Shen MJ, et al. (2016) Accuracy of advanced cancer patients' life expectancy estimates: The role of race and source of life expectancy information. Cancer 122(12), 1905–1912. doi:10.1002/cncr. 30001
- Trice ED, Prigerson HG, Trice ED, et al. (2009) Communication in end-stage cancer: Review of the literature and future research. Journal

- of Health Communication 14(S1), 95-108. doi:10.1080/108107309028 06786
- Van Scoy LJ, Day AG, Howard M, et al. (2019) Adaptation and preliminary validation of the advance care planning engagement survey for surrogate decision makers. *Journal of Pain and Symptom Management* 57(5), 980–8.e9. doi:10.1016/j.jpainsymman.2019.01.008
- Waite KR, Federman AD, McCarthy DM, et al. (2013) Literacy and race as risk factors for low rates of advance directives in older adults. *Journal of the American Geriatrics Society* 61(3), 403–406. doi:10.1111/jgs.12134
- Weeks JC, Cook EF, O'Day SJ, *et al.* (1998) Relationship between cancer patients' predictions of prognosis and their treatment preferences. *JAMA* **279**(21), 1709–1714. doi:10.1001/jama.279.21.1709
- Weissman JS, Reich AJ, Prigerson HG, et al. (2021) Association of advance care planning visits with intensity of health care for Medicare beneficiaries with serious illness at the end of life. *JAMA Health Forum* **2**(7), e211829. doi:10.1001/jamahealthforum.2021.1829
- Winzelberg GS, Hanson LC and Tulsky JA (2005) Beyond autonomy: Diversifying end-of-life decision-making approaches to serve patients and families. *Journal of the American Geriatrics Society* **53**(6), 1046–1050. doi:10. 1111/j.1532-5415.2005.53317.x
- Wright AA, Zhang B, Ray A, *et al.* (2008) Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. *JAMA* **300**(14), 1665–1673. doi:10.1001/jama.300. 14.1665
- Yun YH, Kwon YC, Lee MK, et al. (2010) Experiences and attitudes of patients with terminal cancer and their family caregivers toward the disclosure of terminal illness. *Journal of Clinical Oncology* 28(11), 1950–1957. doi:10.1200/JCO.2009.22.9658
- Zhang AY and Siminoff LA (2003) Silence and cancer: Why do families and patients fail to communicate? *Health Communication* **15**(4), 415–429. doi:10. 1207/S15327027HC1504_03